SCHEMBL5434638

SCHEMBL5434638

Cn1c(=O)[nH]c(=O)c2nc(-c3ccc(Cl)cc3)c(Cl)nc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.47
KMT2A Q03164 5/20 0.47
ALDH1A1 P00352 5/20 0.44
HPGD P15428 4/20 0.44
KDM4E B2RXH2 3/20 0.44
GLA P06280 1/20 0.44
GAA P10253 1/20 0.44
ATM Q13315 1/20 0.44
APOBEC3G Q9HC16 1/20 0.44
TSHR P16473 6/20 0.42
MAPK1 P28482 1/20 0.42
POLB P06746 1/20 0.41
HSD17B10 Q99714 2/20 0.41
KDM1A O60341 1/20 0.41
MAPT P10636 1/20 0.41
PKM P14618 1/20 0.40
USP2 O75604 2/20 0.40
LMNA P02545 2/20 0.40
CYP1A2 P05177 1/20 0.40
TP53 P04637 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5434556 0.91 ALDH1A1 (0.44) MEN1KMT2AALDH1A1HPGDKDM4E
SCHEMBL5454885 0.90 BRDT (0.44) ALDH1A1HPGDKDM4EGLAGAA
SCHEMBL5434692 0.89 KDM4E (0.56) KMT2AALDH1A1HPGDKDM4EGLA
SCHEMBL5437609 0.87 KDM4E (0.47) MEN1KMT2AALDH1A1HPGDKDM4E
SCHEMBL5446767 0.87 KMT2A (0.45) MEN1KMT2AALDH1A1HPGDKDM4E
SCHEMBL5437075 0.86 KDM4E (0.41) MEN1KMT2AALDH1A1HPGDKDM4E
SCHEMBL5435513 0.82 PDE4A (0.42) KMT2AALDH1A1HPGDKDM4ETSHR
SCHEMBL5435686 0.78 XDH (0.45) MEN1KMT2AALDH1A1HPGDKDM4E
SCHEMBL6320759 0.77 KDM4E (0.48) MEN1KMT2AALDH1A1HPGDKDM4E
SCHEMBL5443537 0.75 ALDH1A1 (0.44) MEN1KMT2AALDH1A1HPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070043000-A1 Immunosuppresive effects of pteridine derivatives 4 AZA BIOSCIENCE NV (BE) 2007-02-22 US claimed
EP-1636232-A2 IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES 4 AZA Bioscience nv (BE) 2006-03-22 EP claimed
US-6946465-B2 Immunosuppressive effects of pteridine derivatives 4 AZA BIOSCIENCE NV (BE) 2005-09-20 US claimed
WO-2004104005-A2 IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES 4 AZA BIOSCIENCE NV (BE) 2004-12-02 WO claimed
US-20030236255-A1 Immunosuppressive effects of pteridine derivatives 4 AZA BIOSCIENCE NV (BE) 2003-12-25 US claimed
US-20070043000-A1 Immunosuppresive effects of pteridine derivatives 4 AZA BIOSCIENCE NV (BE) 2007-02-22 US disclosed
EP-1636232-A2 IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES 4 AZA Bioscience nv (BE) 2006-03-22 EP disclosed
US-6946465-B2 Immunosuppressive effects of pteridine derivatives 4 AZA BIOSCIENCE NV (BE) 2005-09-20 US disclosed
WO-2004104005-A2 IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES 4 AZA BIOSCIENCE NV (BE) 2004-12-02 WO disclosed
EP-1479682-A1 Immunosuppressive effects of pteridine derivatives 4 AZA Bioscience nv (BE) 2004-11-24 EP disclosed
US-20030236255-A1 Immunosuppressive effects of pteridine derivatives 4 AZA BIOSCIENCE NV (BE) 2003-12-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043000-A1 Immunosuppresive effects of pteridine derivatives TPMT, FKBP5, RRP15 MEN1 2633/4885KMT2A 1220/4885ALDH1A1 1767/4885
US-20030236255-A1 Immunosuppressive effects of pteridine derivatives TPMT, FKBP5, RRP15 MEN1 2517/4885KMT2A 1154/4885ALDH1A1 1744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.